|
AzurRx BioPharma to Present at the 2017 Biotech Showcase Conference
|
28 Dec, 2016 |
|
AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Exocrine Pancreatic Insufficiency
|
21 Dec, 2016 |
|
WallachBeth Capital Initiates Research Coverage of AzurRx BioPharma
|
12 Dec, 2016 |
|
AzurRx BioPharma Announces Agreement in Principle with TransChem for MTAN Inhibition Technology
|
06 Dec, 2016 |
|
AzurRx CEO Provides Shareholders With a "State of the Union" Communication
|
01 Dec, 2016 |
|
AzurRx BioPharma to Present at the 9th Annual LD Micro Main Event
|
30 Nov, 2016 |
|
AzurRx BioPharma and Mayoly-Spindler Announce Initiation of Phase II Clinical Trial of MS1819-SD for Exocrine Pancreatic Insufficiency in Chronic Pancreatitis Patients
|
17 Nov, 2016 |
|
AzurRx BioPharma Inc. (Nasdaq: AZRX) to Ring The Nasdaq Stock Market Closing Bell
|
19 Oct, 2016 |
|
AzurRx BioPharma Announces Pricing of Initial Public Offering
|
11 Oct, 2016 |
